Symons Capital Management Inc. Has $4.73 Million Stock Position in Celgene Co. (NASDAQ:CELG)

Symons Capital Management Inc. lowered its holdings in shares of Celgene Co. (NASDAQ:CELG) by 8.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 47,629 shares of the biopharmaceutical company’s stock after selling 4,606 shares during the period. Celgene comprises about 2.2% of Symons Capital Management Inc.’s holdings, making the stock its 25th biggest position. Symons Capital Management Inc.’s holdings in Celgene were worth $4,729,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Benjamin F. Edwards & Company Inc. grew its position in shares of Celgene by 56.1% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 7,237 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 2,600 shares during the last quarter. Principle Wealth Partners LLC lifted its holdings in Celgene by 19.6% in the 3rd quarter. Principle Wealth Partners LLC now owns 7,013 shares of the biopharmaceutical company’s stock worth $696,000 after purchasing an additional 1,150 shares during the last quarter. McIlrath & Eck LLC lifted its holdings in Celgene by 253.6% in the 3rd quarter. McIlrath & Eck LLC now owns 488 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 350 shares during the last quarter. First Trust Advisors LP lifted its holdings in Celgene by 1.7% in the 3rd quarter. First Trust Advisors LP now owns 523,581 shares of the biopharmaceutical company’s stock worth $51,992,000 after purchasing an additional 8,650 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its holdings in Celgene by 0.3% in the 3rd quarter. Daiwa Securities Group Inc. now owns 48,322 shares of the biopharmaceutical company’s stock worth $4,799,000 after purchasing an additional 145 shares during the last quarter. 72.31% of the stock is owned by institutional investors.

Several equities research analysts recently weighed in on CELG shares. Wells Fargo & Co set a $110.00 target price on Celgene and gave the stock a “hold” rating in a report on Friday, November 1st. ValuEngine lowered Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday, August 1st. Cowen restated a “hold” rating and issued a $102.00 target price on shares of Celgene in a report on Tuesday, July 30th. BidaskClub upgraded Celgene from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, Robert W. Baird lowered Celgene from an “outperform” rating to a “neutral” rating and set a $101.00 target price for the company. in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, nineteen have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Celgene currently has an average rating of “Hold” and a consensus price target of $97.31.

Shares of CELG stock traded up $0.54 during trading hours on Friday, reaching $109.54. 5,706,800 shares of the company’s stock were exchanged, compared to its average volume of 6,764,924. The company has a quick ratio of 2.80, a current ratio of 2.89 and a debt-to-equity ratio of 1.51. Celgene Co. has a fifty-two week low of $58.59 and a fifty-two week high of $109.75. The business has a fifty day moving average price of $102.54 and a 200-day moving average price of $96.76. The stock has a market capitalization of $76.64 billion, a P/E ratio of 14.39, a P/E/G ratio of 0.51 and a beta of 1.41.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $2.99 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.70 by $0.29. Celgene had a return on equity of 78.15% and a net margin of 34.63%. The company had revenue of $4.52 billion during the quarter, compared to the consensus estimate of $4.39 billion. During the same period in the previous year, the company posted $2.29 EPS. The firm’s revenue for the quarter was up 16.1% compared to the same quarter last year. As a group, research analysts expect that Celgene Co. will post 10.7 EPS for the current fiscal year.

In related news, insider Terrie Curran sold 11,338 shares of Celgene stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the completion of the sale, the insider now directly owns 13,493 shares of the company’s stock, valued at approximately $1,325,957.11. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.39% of the company’s stock.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: How can investors find ex-dividend dates?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.